{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:15:54Z","timestamp":1784891754800,"version":"3.55.0"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T00:00:00Z","timestamp":1487030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["MOP-89993"],"award-info":[{"award-number":["MOP-89993"]}],"id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0172244","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T19:55:59Z","timestamp":1487102159000},"page":"e0172244","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells"],"prefix":"10.1371","volume":"12","author":[{"given":"Simon","family":"Chewchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amadeo Mark","family":"Parissenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S1470-2045(15)00079-0","article-title":"Continued value of adjuvant anthracyclines as treatment for early breast cancer","volume":"16","author":"N Turner","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0009-2797(81)90120-4","article-title":"Comparative inhibition of nuclear RNA synthesis in cultured mouse leukemia L1210 cells by adriamycin and 4'-epi-adriamycin","volume":"37","author":"RG Wilson","year":"1981","journal-title":"Chem Biol Interact"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0167-4781(83)90124-0","article-title":"Interaction of new anthracycline antibiotics with DNA. Effects on nucleic acid synthesis and binding to DNA","volume":"740","author":"T Komiyama","year":"1983","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"ref4","first-page":"235","article-title":"Mechanisms of resistance to drugs that inhibit DNA topoisomerases","volume":"2","author":"WT Beck","year":"1991","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.leukres.2012.02.017","article-title":"Adriamycin dose and time effects on cell cycle, cell death, and reactive oxygen species generation in leukaemia cells","volume":"36","author":"J Savatier","year":"2012","journal-title":"Leuk Res"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"e58421","DOI":"10.1371\/journal.pone.0058421","article-title":"Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse","volume":"8","author":"S Toldo","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF01240142","article-title":"Modulation of Doxorubicin-Toxicity by Tamoxifen in Multidrug-Resistant Tumor-Cells In-Vitro and In-Vivo","volume":"120","author":"E Pommerenke","year":"1994","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000092540","article-title":"Molecular markers of multiple drug resistance in breast cancer","volume":"52","author":"L O'Driscoll","year":"2006","journal-title":"Chemotherapy"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/1756-0500-6-254","article-title":"Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report","volume":"6","author":"K Ishizuna","year":"2013","journal-title":"BMC Res Notes"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/01.coc.0000245475.41324.6d","article-title":"A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer","volume":"30","author":"MF Gaui","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1200\/EdBook_AM.2013.33.73","article-title":"Drug development: neoadjuvant opportunities in breast cancer","author":"P Rastogi","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/1471-2407-8-318","article-title":"Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance","volume":"8","author":"SL Hembruff","year":"2008","journal-title":"BMC cancer"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/FPC.0b013e32832c484b","article-title":"Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance","volume":"19","author":"ZW Veitch","year":"2009","journal-title":"Pharmacogenetics and genomics"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/1471-2407-12-381","article-title":"Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization","volume":"12","author":"AD Heibein","year":"2012","journal-title":"BMC cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev.pharmtox.47.120505.105337","article-title":"Aldo-keto reductases and bioactivation\/detoxication","volume":"47","author":"Y Jin","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03602530802431439","article-title":"The aldo-keto reductase superfamily and its role in drug metabolism and detoxification","volume":"40","author":"OA Barski","year":"2008","journal-title":"Drug Metab Rev"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.steroids.2005.12.002","article-title":"Molecular docking simulations of steroid substrates into human cytosolic hydroxysteroid dehydrogenases (AKR1C1 and AKR1C2): Insights into positional and stereochemical preferences","volume":"71","author":"Y Jin","year":"2006","journal-title":"Steroids"},{"issue":"1\u20132","key":"ref18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0303-7207(00)00426-3","article-title":"Structure-function aspects and inhibitor design of type 5 17 beta-hydroxysteroid dehydrogenase (AKR1C3)","volume":"171","author":"TM Penning","year":"2001","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"1\u20132","key":"ref19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0303-7207(00)00389-0","article-title":"Structure and function of 17 beta-hydroxysteroid dehydrogenase type 1 and type 2","volume":"171","author":"P Vihko","year":"2001","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"1\u20132","key":"ref20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.mce.2005.10.009","article-title":"AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer","volume":"248","author":"TL Rizner","year":"2006","journal-title":"Molecular and Cellular Endocrinology"},{"issue":"27","key":"ref21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/oxfordjournals.jncimonographs.a024237","article-title":"Estrogen receptor-mediated processes in normal and cancer cells","author":"RB Dickson","year":"2000","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/bcr3166","article-title":"ER and PR signaling nodes during mammary gland development","volume":"14","author":"T Tanos","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"1\u20132","key":"ref23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10911-015-9337-0","article-title":"Form and Function: how Estrogen and Progesterone Regulate the Mammary Epithelial Hierarchy","volume":"20","author":"LM Arendt","year":"2015","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"3\u20135","key":"ref24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jsbmb.2007.09.012","article-title":"Intracrinology of estrogens and androgens in breast carcinoma","volume":"108","author":"H Sasano","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2265.1983.tb00051.x","article-title":"The Relationship Between 17-Beta-Hydroxysteroid Dehydrogenase-Activity and Estrogen Concentrations in Human-Breast Tumors and in Normal Breast-Tissue","volume":"19","author":"RC Bonney","year":"1983","journal-title":"Clinical Endocrinology"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2004.11.004","article-title":"Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells","volume":"93","author":"J Shields-Botella","year":"2005","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-0760(03)00390-X","article-title":"Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells","volume":"87","author":"J Russo","year":"2003","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"issue":"5331","key":"ref28","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.277.5331.1508","article-title":"Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites","volume":"277","author":"K Paech","year":"1997","journal-title":"Science"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1016\/S0021-9258(17)41801-1","article-title":"Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity","volume":"269","author":"P Le Goff","year":"1994","journal-title":"J Biol Chem"},{"issue":"9\u201310","key":"ref30","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.steroids.2007.12.028","article-title":"MNAR plays an important role in ERa activation of Src\/MAPK and PI3K\/Akt signaling pathways","volume":"73","author":"BJ Cheskis","year":"2008","journal-title":"Steroids"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1196\/annals.1386.006","article-title":"Crosstalk between EGFR and extranuclear steroid receptors","volume":"1089","author":"A Migliaccio","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"ref32","first-page":"254","article-title":"Oestrogen- and anti-oestrogen-regulated genes in human breast cancer","volume":"191","author":"H Rochefort","year":"1995","journal-title":"Ciba Found Symp"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.mce.2013.06.021","article-title":"Hormone-regulated transcriptomes: lessons learned from estrogen signaling pathways in breast cancer cells","volume":"382","author":"N Hah","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1095\/biolreprod.105.050070","article-title":"Membrane initiated estrogen signaling in breast cancer","volume":"75","author":"RX Song","year":"2006","journal-title":"Biol Reprod"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/bcr2255","article-title":"Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?","volume":"11","author":"JS Lewis-Wambi","year":"2009","journal-title":"Breast Cancer Res"},{"issue":"9","key":"ref36","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/embo-reports\/kve185","article-title":"Estrogen receptors: orchestrators of pleiotropic cellular responses","volume":"2","author":"JG Moggs","year":"2001","journal-title":"Embo Reports"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.2010.30.3677","article-title":"Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial","volume":"29","author":"JM Bartlett","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3816\/CBC.2008.n.003","article-title":"Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease","volume":"8","author":"CI Herold","year":"2008","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejon.2008.01.007","article-title":"The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer","volume":"12","author":"E Pennery","year":"2008","journal-title":"Eur J Oncol Nurs"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3892\/etm.2015.2380","article-title":"Expression and prognostic value of estrogen receptor beta in patients with triple-negative and triple-positive breast cancer","volume":"9","author":"L Guo","year":"2015","journal-title":"Exp Ther Med"},{"issue":"9","key":"ref41","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00432-013-1467-4","article-title":"Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma","volume":"139","author":"NI Chantzi","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ab.2005.07.014","article-title":"The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data","volume":"345","author":"SL Hembruff","year":"2005","journal-title":"Anal Biochem"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1043-2760(02)00634-3","article-title":"Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling","volume":"13","author":"PH Driggers","year":"2002","journal-title":"Trends in Endocrinology and Metabolism"},{"issue":"1\u20132","key":"ref44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0303-7207(98)00095-1","article-title":"Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors","volume":"141","author":"PT Ram","year":"1998","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1210\/en.2010-1281","article-title":"Phosphorylation of Estrogen Receptor alpha at serine 118 directs recruitment of promoter complexes and gene-specific transcription","volume":"152","author":"TT Duplessis","year":"2011","journal-title":"Endocrinology"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0039-128X(02)00110-1","article-title":"Estrogen receptor phosphorylation","volume":"68","author":"DA Lannigan","year":"2003","journal-title":"Steroids"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jcb.22922","article-title":"Furanodienone inhibits cell proliferation and survival by suppressing ERalpha signaling in human breast cancer MCF-7 cells","volume":"112","author":"YW Li","year":"2011","journal-title":"J Cell Biochem"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6690706","article-title":"Paradoxical regulation of Bcl-2 family proteins by 17 beta-oestradiol in human breast cancer cells MCF-7","volume":"81","author":"LK Leung","year":"1999","journal-title":"British Journal of Cancer"},{"issue":"3","key":"ref49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.taap.2014.04.027","article-title":"Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3","volume":"278","author":"J Hofman","year":"2014","journal-title":"Toxicology and applied pharmacology"},{"issue":"8","key":"ref50","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/CAD.0000000000000112","article-title":"Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells","volume":"25","author":"T Matsunaga","year":"2014","journal-title":"Anti-cancer drugs"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.steroids.2013.10.012","article-title":"Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism","volume":"79","author":"TL Rizner","year":"2014","journal-title":"Steroids"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1043-2760(01)00377-0","article-title":"Rapid actions of plasma membrane estrogen receptors","volume":"12","author":"MJ Kelly","year":"2001","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"ref53","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1210\/en.2005-1314","article-title":"Classical genotropic versus kinase-initiated regulation of gene transcription by the estrogen receptor alpha","volume":"147","author":"M Almeida","year":"2006","journal-title":"Endocrinology"},{"issue":"5","key":"ref54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0960-0760(01)00117-0","article-title":"Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens","volume":"78","author":"ME Burow","year":"2001","journal-title":"Journal of Steroid Biochemistry and Molecular Biology"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2014.12.022","article-title":"Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss","volume":"69","author":"T Zhong","year":"2015","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"ref56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jsbmb.2009.12.009","article-title":"Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer","volume":"118","author":"MC Byrns","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"ref57","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.bjc.6605360","article-title":"Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer","volume":"101","author":"T Hirata","year":"2009","journal-title":"Br J Cancer"},{"issue":"4","key":"ref58","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.hoc.2013.05.004","article-title":"Endocrine therapy for advanced\/metastatic breast cancer","volume":"27","author":"G Schiavon","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"ref59","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/CAD.0b013e3282f97f75","article-title":"Neoadjuvant endocrine therapy for breast cancer: past, present and future","volume":"19","author":"A Barnadas","year":"2008","journal-title":"Anticancer Drugs"},{"issue":"1","key":"ref60","first-page":"349","article-title":"Effect of estradiol on human breast cancer cells in culture","volume":"43","author":"P Darbre","year":"1983","journal-title":"Cancer Res"},{"issue":"3","key":"ref61","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3390\/cells1030284","article-title":"Regulation of the autophagic bcl-2\/beclin 1 interaction","volume":"1","author":"JP Decuypere","year":"2012","journal-title":"Cells"},{"issue":"12","key":"ref62","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/carcin\/bgn214","article-title":"Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells","volume":"29","author":"SN Sundar","year":"2008","journal-title":"Carcinogenesis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0172244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T04:12:40Z","timestamp":1658635960000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0172244"}},"subtitle":[],"editor":[{"given":"Aamir","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,14]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0172244","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,14]]}}}